TransMedics Group, Inc.
TMDXNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for TMDX. That does not mean none is planned.
Get an email about TMDX's next catalysts
Track TransMedics Group (TMDX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
PF-04494700 - High Dose Arm | Phase 2 | Alzheimer Disease | - | - |
Frequently asked questions
What is in TransMedics Group, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in TransMedics Group, Inc.'s (TMDX) pipeline across Phase 2. Its lead program is PF-04494700 - High Dose Arm (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is TransMedics Group, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for TransMedics Group, Inc. (TMDX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track TMDX biotech catalysts?→
Add TMDX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TransMedics Group, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.